BioNTech Shares Surge on Regulatory Win and Analyst Confidence
Published on 09/26/2025 at 16:00 | Redaktion boerse-global.de
A significant regulatory decision from U.S. health authorities sparked a notable rally for BioNTech stock on Monday, with shares climbing nearly 3%. This surge was further bolstered by a major investment bank raising its price target, prompting speculation about a potential turnaround for the vaccine developer’s recently underperforming equity.
Providing substantial momentum, JP Morgan increased its price objective for BioNTech to $121. This new target, set from a current trading level around $102, indicates a belief in considerable upside potential. The positive sentiment is echoed by HC Wainwright & Co., which maintains a Buy rating and an even more optimistic $136 price target.
The primary catalyst for the upward move was a Friday evening decision by a key committee advising the... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
